Precision medicine has come a long way in terms of breast cancer treatment but more needs to be done for the non-responder patients, for those who need financial support, for minorities. Precision cancer care needs to be available for all.
Frederick Howard, MD, a medical oncology fellow in the Department of Medicine at the University of Chicago, discussed the clinical benefits of the SimBioSys TumorScope model for the treatment of early breast cancer in an interview with Targeted Oncology. Even…
[et_pb_section fb_built=”1″ _builder_version=”4.10.8″ _module_preset=”default” background_color=”#FFFFFF” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”2_5,3_5″ _builder_version=”4.10.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”2_5″ _builder_version=”4.10.8″ _module_preset=”default” global_colors_info=”{}”][/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.10.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.10.8″ _module_preset=”default” global_colors_info=”{}”] Thank you for your interest in our white paper. [/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row column_structure=”2_5,3_5″ _builder_version=”4.10.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”2_5″ _builder_version=”4.10.8″ _module_preset=”default” global_colors_info=”{}”][et_pb_text…
Genoa Ventures and Northpond Ventures co-lead investment in precision medicine platform that develops virtual tumors in 3D to predict response to therapy using standard-of-care data
Background: Dysregulated cellular metabolism is a hallmark of breast cancer, and targeting it has promising implications for improving care and patient outcomes. Specifically, heterogeneity in tumor metabolism is thought to play a role in determining chemotherapy response, the development of…
Background: Breast Cancer (BC) patients exhibit a wide variety of responses to neoadjuvant chemotherapy (NACT). This is driven by factors both intrinsic (e.g., mutations, dysregulation, metabolic reprogramming) and extrinsic (e.g., nutrient/drug perfusion, interactions with surrounding healthy tissues and the tumor…
Background: Clinical trials can be logistically burdensome, financially expensive, and potentially detrimental to patient outcomes. The NeoSphere study, which investigated the efficacy of docetaxel (T), pertuzumab (P), and trastuzumab (H) in combination with one another, was performed recently over an…
Background: Pathological complete response (pCR) is a well validated endpoint for early-stage breast cancer (EBC) patients treated with neoadjuvant chemotherapy (NAT), with a strong correlation with long term outcomes such as event free survival (EFS) and overall survival (OS). However,…
Background: Immunotherapy (IO) is expected to become a part of standard neoadjuvant therapy for early-stage, triple-negative breast cancer. However, only a minority of patients benefit from the addition of IO to standard neoadjuvant chemotherapy (NACT). Biomarkers of IO response in…
Background: Dynamic contrast-enhanced (DCE) MRI has long been used in the diagnosis and treatment planning of cancers. Chief among its use is the identification of tumors in soft tissues, where the tumor progression-induced angiogenic changes result in leaky vasculature which…
SOLUTIONS
RESOURCES
©SimBioSys